Couverture de HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

 Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological cancers, showing promising results even in patients with low HER2 expression. They shared impressive clinical trial successes while emphasizing the importance of ongoing research into treatment sequencing and patient safety.
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Aucun commentaire pour le moment